review will consider whether nitric oxide (NO) contributes to maternal systemic vasodilation during pregnancy, regulates uterine and fetoplacental blood flow, and is involved in uterine quiescence prior to parturition.
Also, whether a deficiency of NO contributes to the hypertensive disorder of pregnancy, preeclampsia, will be considered. The biosynthesis of NO increases in gravid rats and sheep, but the status in normal human pregnancy and preeclampsia is controversial.
NO contributes to maternal systemic vasodilation and reduced vascular reactivity during normal pregnancy; however, the relative contribution of NO is variable depending on the animal species, vascular bed, and vessel size. Impaired relaxation responses to acetylcholine, but not bradykinin or NO donors, are observed in small arteries from women with preeclampsia, suggesting a receptor or signal transduction defect, although NO may play little, if any, role here. Uterine arteries have increased endothelial nitric oxide synthase (NOS) activity, protein expression, and guanosine 3',5'-cyclic monophosphate production during pregnancy; however, whether these mediate uterine vasodilation during pregnancy remains to be established. NOS is expressed in the human placental syncytiotrophoblast and in the fetoplacental and umbilical vascular endothelium where basal production of NO contributes to low fetoplacental vascular resistance. Controversy exists over the status of placental NOS in preeclampsia, although an abnormality of umbilical NOS activity is likely Finally, the uterus has NOS activity, which decreases at the end of gestation, and exogenous NO relaxes the myometrium, but whether endogenous NO contributes to uterine quiescence during pregnancy has yet to be confirmed. vascular smooth muscle; endothelium-derived relaxing factor; guanosine 3',5'-cyclic monophosphate; nitric oxide synthase; uterine artery; placenta; trophoblast; umbilical vessels; kidney; preeclampsia; myometrium; decidua; uterus; parturition THE OBJECTIVE OFTHISREVIEW is to analyze the evidence that nitric oxide (NO), an endogenous relaxant of smooth muscle, is involved in three crucial physiological adaptations of mammalian pregnancy: 1) vasodilation of the maternal systemic circulation, 2) increased uterine and fetoplacental blood flow, and 3) quiescence of the uterus before parturition. The potential contribution of NO deficiency to the pathogenesis of preeclampsia (a pregnancy-specific disease characterized by vasospasm, capillary leak, and coagulopathy) is also evaluated.
MATERNAL SYSTEMIC CIRCULATION
Vasodilation of the maternal systemic circulation typifies normal pregnancy in humans and other mammalian species, such as sheep and rodents. Cardiac output, renal blood flow, and glomerular filtration rate (GFR) increase by 30-60%. Furthermore, pressor responsiveness or vascular reactivity to several vasoconstrictors is attenuated. This section addresses the potential contribution of NO to the vasodilatory phenomena of pregnancy.
NO and cGMP Biosynthesis During Normal Pregnancy and Preeclampsia Conrad et al. (39, 42, 44) hypothesized that guanosine 3',5'-cyclic monophosphate (cGMP), a second messenger of endothelium-derived relaxing factor (EDRF)/ NO, mediates maternal vasodilation in normal pregnancy. Because extracellular levels of cGMP reflect intracellular production .Y they investigated the plasma concentration, urinary excretion, and metabolic pro-
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INVITED REVIEW duction rate of cGMP in conscious rats and observed increases in these parameters throughout pregnancy and pseudopregnancy (39, 42, 44) . Similar increases in urinary excretion and plasma concentration of cGMP were reported for human gestation (43, 119, 208) .
The urinary excretion of nitrite and nitrate (NOx) also increased during pregnancy and pseudopregnancy in rats consuming a low-NOx diet, paralleling the rise in urinary cGMP excretion (42). The gestational rise in urinary NOx was inhibited by chronic infusion of nitro-L-arginine methyl ester (L-NAME). Plasma levels of NOx were also increased during pregnancy, and NO-hemoglobin was detected in the red blood cells of pregnant rats, but was not detected in the red blood cells of nonpregnant rats (42). These results demonstrated that endogenous NO production is increased in gravid rats and raised the possibility that NO may contribute to maternal vasodilation. Similar increases in plasma levels and urinary excretion of NOx were recently reported for gravid ewes (256).
The status of NO biosynthesis during normal pregnancy in women is controversial.
Seligman and colleagues (214) reported that serum concentrations of NOx were slightly, but significantly, increased compared with nonpregnant women. Myatt et al. (170) observed increases in urinary NOx excretion in single voided urine samples. In contrast, other investigators failed to observe increases in plasma concentration and urinary excretion of NOx (25, 43, 48) or in exhaled NO during human pregnancy (166). Because dietary intake of NOx markedly affects urinary excretion (84, and Conrad, unpublished data) , it needs to be restricted and precisely controlled, so that urinary excretion mainly reflects endogenous production rather than dietary intake. With one exception (43), the dietary intake of NOx was not controlled. Thus the longitudinal analysis of 24-h urine samples from the same women before, during, and after pregnancy, in which the dietary intake of NOx is controlled, may resolve whether NO biosynthesis increases during gestation in women. If NO biosynthesis is not increased, then other mediator (s) may produce the elevations of cGMP and vasodilation during human pregnancy. In this regard, Sala and colleagues (208) showed a correlation between supine plasma atria1 natriuretic peptide (ANP) and cGMP concentrations in gravid women. A recent metaanalysis of 53 studies, however, demonstrated an increase in plasma ANP by 41%, but only in the third trimester (31). In contrast, cGMP peaks in the first trimester (coincident with the maximum vasodilatory responses) and remains increased throughout pregnancy (43, 119, 208) . It is possible that other mediators of cGMP production, including carbon monoxide [synthesized in the vascular wall by the enzyme heme oxygenase (46)], the peripheral benzodiazepine receptor (68), or catalase compound I (28) are involved. Alternatively, vascular smooth muscle (VSM) may become more sensitive to NO during human pregnancy, thereby generating more cGMP and producing vasodilation.
No difference in the relaxation to sodium nitroprusside (SNP), however, was observed between subcutaneous blood vessels from nonpregnant and normal pregnant women (154). Finally, one cannot exclude the possibility that local NO production (and action) increases only in certain vascular beds (e.g., the kidney and uterus), which is obscured by the analysis of whole body synthesis in women.
Whether NO biosynthesis is reduced in preeclampsia is also controversial.
Several investigators did not find any differences in urinary excretion or plasma levels of NOx between normal pregnant and preeclamptic women (25, 30, 48) . Th In human studies using venous occlusion plethysmography, hand blood flow was reduced to a greater extent in pregnant than in nonpregnant women during infusion of L-NMMA into the brachial artery, suggesting greater NO activity in this circulation during pregnancy (250). NO activity was also reported to be increased in the superficial venous vasculature of the hand during the immediate postpartum period (72).
Finally, chronic administration of NOS inhibitors to gravid rats produced hypertension, proteinuria, thrombocytopenia, and reduced plasma volume and newborn weights, abnormalities reminiscent of preeclampsia (14, 42, 62, 162, 209, 253) . Nonpregnant rats treated identically showed similar abnormalities, but to a lesser degree. These studies suggest that if production of NO is reduced in preeclampsia then the deficiency could contribute to disease manifestations.
NO in Isolated Vessel Preparations: Stimulated Production
Production of endothelial NO stimulated in isolated vessels from pregnant animals and women has been investigated by evaluating vascular relaxation or cGMP accumulation to agonists such as acetylcholine (ACh) and the calcium ionophore A-23187, receptor-dependent and -independent vasodilators, respectively. By inhibiting the NO/cGMP pathway of relaxation with arginine analogs, methylene blue or reduced hemoglobin, the relative contribution of NO to the relaxation response has been determined.
Methylene blue inhibits NOS or NO activation of soluble guanylate cyclase (sGC; 153), and reduced hemoglobin binds and inactivates NO (151). The mediators of vascular relaxation to any given agonist are frequently dependent on the vessel size, organ bed, and animal species of origin. In addition to NO, prostaglandins, endothelium-derived hyperpolarizing factor (EDHF), and other mediators may be involved. SNP has been commonly used as a pharmacological NO donor to assess the inherent capacity of the vessel for endothelium-independent relaxation by NO.
Guinea pig. The carotid artery from the guinea pig of 50-60 gestational days (term = 65-68 days) was more sensitive and produced a greater maximal relaxation to ACh in some (239, 242), but not all (243, 244), reports. 1O-5 M) . Accumulation of cGMP in response to SNP, A-23187, bradykinin, or mellitin was not significantly different, whereas for histamine, it was reduced in the vessels from gravid rats (247). Similar to the conclusion reached by Gregg and colleagues (86) for the guinea pig aorta, an alteration of the ACh (and histamine) receptor or signal transduction pathway in the aorta from pregnant rats was postulated.
Significant reductions in ECsO were consistently observed for ACh (or methacholine) relaxation of resistance-sized vessels from the renal and mesenteric circulation of late pregnant rats (53, 89, 191 women. Blockade of cyclooxygenase slightly reduced, and subsequent addition of L-NAME more completely inhibited, the relaxation response to ACh in vessels from nonpregnant and pregnant women. An impressive degree of relaxation remained despite blockade of both cyclooxygenase and NOS, suggesting an additional mediator such as EDHF. Endotheliumdependent relaxation to ACh was impaired in the subcutaneous small arteries from preeclamptic women compared with normal pregnant subjects (155). The E& was greater, and the maximum relaxation was reduced. Whether the affected component was a cyclooxygenase product, NO, or another endotheliumdependent vasodilator was not clearly determined in this study. The endothelium-independent relaxation to SNP was comparable in the vessels from preeclamptic and normal women. Pascoal et al. (190) studied small arteries from the omentum of preeclamptic and normal pregnant women. They demonstrated that the vessels from normal pregnant women completely relaxed to ACh and bradykinin in an endothelium-dependent, but NO-independent, manner. The vessels from preeclamptic women showed normal responses to bradykinin, but absent responses to ACh. SNP completely relaxed vessels from both groups.
NO in Isolated Vessel Preparations: Basal Production
Guinea pig. In carotid arteries from nonpregnant and pregnant guinea pigs of 50-60 gestational days, vasoconstrictor responses to NE, U-46619 (a thromboxane analog), and prostaglandin Fza (PGF2,) were comparable (239, 243, 244) . Inhibitors of NOS increased vascular reactivity to these agonists, but equally so in the vessels from nonpregnant and pregnant animals.
Rat. In the superior mesenteric artery and thoracic aorta of the late gravid rat, vasoconstrictor responses to phenylephrine and NE were attenuated (189, 207) . However, based on the correlation with ACh relaxation or inhibition of NOS with L-NMMA, the attenuated responsiveness to adrenergic agonists was not mediated by NO. Whittemore et al. (247) found that basal levels of aortic cGMP were not significantly different between gravid and virgin rats, whether the vessels were incubated in the presence or absence of the phosphodiesterase inhibitor isobutyl-l-methyl xanthine (IBMX) or L-arginine. Furthermore, reduced hemoglobin or endothelial removal decreased cGMP to the same level in the aortas from the two groups of rats. These results suggest that basal production of NO by type III endothelial cell nitric oxide synthase (ecNOS) is comparable and that type II inducible nitric oxide synthase (iNOS) is not expressed in the aortic vascular smooth muscle (VSM) during rat gestation. Furthermore, Ca2+ -sensitive NOS activity, as assessed by Larginine-to+citrulline conversion, was not different in aortas from gravid and virgin rats [gravid rats, n = 5: maximal velocity (V,,,) = 1.1 * 0.3 pmol~mg-l~min-l and Michaelis constant (K,) = 0.6 t 0.1 uM; virgin rats, n = 5: Vmax = 1.0 t 0.3 pmol l mg-l l rnin-l and K = 0.5 t 0.1 uM; Conrad, unpublished data] . Ca2+-insensitive NOS activity was 15-fold less than the Ca2+-sensitive activity and also was not significantly different between pregnant and nonpregnant rats. Of course, these findings do not exclude the possibility that circulating hormones or increased shear stress augment vascular NO production by increasing endothelial cell calcium in vivo. In contrast, Goetz et al. (82) reported a twofold increase in mRNA transcripts for ecNOS in the aorta of pregnant rats.
Whether NO mediates reduced vascular reactivity to vasoconstrictors in small arteries or resistance vasculature of gravid rats is controversial. The sensitivity to phenylephrine was reduced by 35% in small mesenteric arteries from late pregnant rats compared with virgin controls (53). L-NAME or endothelial removal produced a twofold increase in phenylephrine sensitivity in the vessels from both groups of rats, such that the attenuated response of pregnancy persisted. In mesenteric arteries of the same caliber, Pascoal et al. (191) observed a comparable phenylephrine vasoconstrictor response between vessels from nonpregnant and late pregnant rats that was potentiated twofold by L-NNA in both groups of animals. Furthermore, Ca2+-sensitive NOS activity of the mesenteric arterial arcade as assessed by L-arginine-to+citrulline conversion was not significantly different (gravid rats, n = 5: Vmax = 4.3 t 1.5 pmol~mg-l~min-l and K, = 0.6 ? 0.2 uM; virgin rats, n = 5: Vmax = 3.9 t 0.4 pmol~mg-l~min-l and K, = 0.6 t 0.1 M; Conrad, unpublished data). Ca2+-insensitive NOS activity was 30-fold less than the Ca2+-sensitive activity and was also not significantly different between nonpregnant and pregnant rats.
In small arteries of the kidney, Griggs and colleagues (89) observed a similar dose response of phenylephrine constriction in the vessels from nonpregnant and late pregnant rats. Removal of endothelium or application of L-NNA increased the sensitivity by 1.5 X and 3.5 X in the vessels from gravid and virgin rats, respectively. Thus basal NO activity was apparently reduced in the renal vessels during late gestation, and in the absence of endothelium, the renal vessels from late pregnant rats manifested attenuated reactivity to phenylephrine, suggesting alteration of VSM function. The basal tone of these small arteries was also reduced in late pregnancy, but apparently not by NO as reduced basal tone persisted despite endothelial removal (91). In fact, the basal tone of the renal arteries from nonpregnant rats was reduced to pregnant levels by endothelial removal, suggesting deficient production of, or VSM response to, an endothelium-derived vasoconstrictor in the vessels from rats during late gestation.
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The tone of the small renal arteries is also reduced during midgestation in the rat at a time when renal vascular resistance is most decreased, and renal plasma flow and GFR increased by 20-40% compared with nonpregnant values (Fig. lC, Refs. 51, 77) . At this gestational stage (and in contrast to the findings obtained during late gestation), L-NAME equalized tone in the small renal arteries from pregnant and nonpregnant rats, indicating an important contribution of NO. Thus the in vitro results are consistent with the in vivo findings discussed previously, which supports a role for NO in the renal vasodilation and hyperfiltration of rat pregnancy.
Other investigators have examined the role of NO in the control of vascular reactivity during pregnancy in the isolated hindlimb and the in situ perfused mesentery of the rat. Baseline perfusion pressure and vascular reactivity to NE were not significantly different in the isolated hindlimbs of nonpregnant and late pregnant rats, and L-NMMA did not affect either parameter (3). In contrast, the vascular reactivity to ANG II was significantly reduced in the hindlimb of gravid rats, and it was restored to nonpregnant levels by L-NMMA (Fig. 2; Ref. 3) . In all experiments, the perfusate contained indomethacin in order to inhibit prostaglandin production.
Using the in situ perfused mesentery preparation, Chu and Beilin (35) observed comparable baseline perfusion pressures in the preparations from nonpregnant and pregnant rats, which were potentiated by L-NNA to the same extent. They found the vascular reactivity to electrical stimulation, NE, and ANG II to be reduced in pregnancy. L-NNA enhanced the vascular reactivity of all vasoconstrictors in the preparations from both pregnant and nonpregnant rats, but only the response to NE was equalized in the two groups of animals. Based on the results of Chu and Beillin (35) using indomethacin, cyclooxygenase products were not responsible for any decreased contractile responses in the preparation from gravid rats. Human. The tension development in response to NE or NE plus KC1 was similar in small subcutaneous arteries from nonpregnant, normal pregnant, and preeclamptic women (154, 155) . In contrast, the response to NE was enhanced in inferior epigastric arteries from preeclamptic women (65). Increased reactivity to arginine vasopressin and KC1 was noted by Pascoal et al. (190) in small omental arteries from preeclamptic women. Both basal and agonist-stimulated vascular oscillations have also been noted in vessels from preeclamptic women, which were absent or decreased in vessels from normal pregnant women (1, 66, 190) . However, whether endothelial impairment and NO deficiency contribute to these abnormalities in vessel behavior from preeclamptic women remains to be tested.
To summarize, the capacity of the pregnant condition to augment stimulated production of endotheliumderived NO was inconsistently observed and apparently depended on several factors including the agonist employed, and on the type of vessel being tested. Many investigators reported that conduit vessels, such as the thoracic aorta and superior mesenteric artery from pregnant and nonpregnant rats, demonstrated comparable relaxation to ACh or methacholine, which was mediated by NO. In the distal aorta of the pregnant guinea pig, however, relaxation to ACh was enhanced and dependent on NO. Because A-23187 produced comparable relaxation in these vessels from nonpregnant and pregnant guinea pigs, a modification of the ACh receptor or signal transduction pathway was suggested. On the other hand, in resistance-sized renal and mesenteric arteries from rats, gestation augmented NO release by ACh. Comparable relaxation responses to ACh were observed in small subcutaneous arteries of normal pregnant and nonpregnant women, although NO was not the only mediator involved. Impaired relaxation responses to ACh, but not to bradykinin or SNP, were observed in small arteries from preeclamptic women, suggesting impairment of the ACh receptor or signal transduction pathway. The response to the endothelium-independent vasodilator SNP was consistently similar between vessels from nonpregnant and pregnant animals, including hu- mans, indicating that the signal transduction pathway distal to NO is unchanged by pregnancy.
Based on functional behavior, cGMP content, or NOS activity, many but not all investigators observed comparable basal production of NO in conduit and small arteries between nonpregnant and pregnant animals. Of course, these in vitro findings do not exclude the possibility that circulating hormones or blood flow per se augment vascular NO production during pregnancy in vivo. In contrast, NO apparently mediates the decreased tone of small arteries from the rat kidney during midgestation, but not late gestation. Furthermore, the diminished vascular reactivity to ANG II and NE was restored to nonpregnant levels by NOS inhibitors in the isolated hindlimb and in situ perfused mesentery preparation of late gravid rats, respectively. Whether alteration of basal NO production occurs in blood vessels from normal pregnant and preeclamptic women has not been tested.
UTERINE ARTERY
Uteroplacental blood flow increases 15 to ZO-fold during pregnancy so that by the third trimester it receives 15-20% of cardiac output (138, 147, 201, 202) .
This dramatic rise in flow maintains normal oxygen and nutrient delivery to the fetoplacental unit (147, 199, 201, 202) . Production of vasodilators by the uterine artery is thought to mediate the pregnancy-induced vasodilatory and attenuated vasoconstrictor responses in the uterine circulation (137) (138) (139) 143) . This section deals with NO production by uterine arteries in pregnancy by evaluating: 1) effects of NO stimulators or inhibitors on uterine blood flow in vivo; 2) NO production and vascular tone in vitro; 3) alterations in uterine artery ecNOS specific activity and cGMP production; and 4) uterine artery NOS isoform expression at the level of protein and mRNA.
In Vivo Actions of Stimulators or Inhibitors of NO on Uterine Blood Flow
When the uterine vascular bed is considered, important information can be gleaned from literature published before the discovery of NO by Furchgott and Zawadszki (76) . In the pregnant sheep model made hypertensive by infusion of NE, administration of SNP partially offsets both the systemic hypertensive effects and the decrease in uterine perfusion (246). However, when hypertension was induced using phenylephrine infusion or one-kidney hypertension, no change (200) and even decreases (135) in uterine blood flow were observed during treatment with SNP. Because the uterine circulation is not autoregulated, it needs to be evaluated in terms of changes in resistance and redistribution of flow, as well as perfusion pressure. Uterine, as opposed to systemic circulatory, responses are best interpreted when vasodilators are infused directly into the uterine circulation. From these studies (135, 200, 246) , one can conclude that the uterine vascular bed is capable of vasodilating in response to exogenous NO in vivo.
Stimulators of endogenous NO (ACh, bradykinin, and histamine) dramatically increase uterine blood flow when infused directly into the uterine circulation of chronically instrumented nonpregnant and/or pregnant sheep (87, 198) . It is unknown if the uterine vasodilatory responses to these agents are blocked by NOS inhibitors. Of related interest to pregnancy, estrogen-induced uterine hyperemia in nonpregnant sheep was reversed by local infusion of L-NAME, implying mediation by NO (203, 234) . These data must be viewed with caution, however, as local infusion of L-NAME into the uterine circulation of pregnant sheep does not consistently alter uterine perfusion (203) .
The uterine vascular bed may contribute to the high circulating levels of cGMP and NO metabolites in pregnancy. We have noted a positive uterine venousarterial concentration difference of cGMP in pregnant sheep and a 38fold increase in uterine cGMP secretion during pregnancy (144, 203) . Systemic and uterine plasma cGMP levels are decreased with L-NAME administration in pregnant sheep (203), confirming that the rise is due to increased NO. Elevations of systemic plasma and urinary cGMP levels in ovine pregnancy are directly correlated with uterine, but not systemic, artery endothelial ecNOS protein expression (145).
In Vitro Vasoconstrictor and Relaxation Responses
Uterine artery smooth muscle relaxes on stimulation of sGC since SNP vasodilates NE-precontracted uterine arteries obtained from nonpregnant or pregnant guinea pigs (239), dogs (152), rats (182), sheep (146), and women (180). Relaxation responses to SNP were similar in uterine arteries from pregnant and nonpregnant rats (182) and women (lSO>, suggesting no difference in VSM sensitivity to NO. In contrast, Weiner et al. (239) reported that the vasodilatory response of the guinea pig uterine artery to SNP was reduced in pregnancy and suggested that this difference was due to an increased basal production of NO, which may downregulate smooth muscle sGC. Classically the release of NO has been evaluated in vascular rings, strips, or pressurized microvessels by studying the effects of pregnancy, endothelium removal, or NOS inhibitors on either vasoconstrictor responses (Table 1) or vasorelaxation responses of precontracted vessels (Table 2) .
There are conflicting data on the sensitivity of uterine arteries from pregnant and nonpregnant animals to vasoconstriction by adrenergic agents in vitro (Table 1) . The vasoconstrictive effects of phenylephrine and metaraminol (q-adrenergic agonists) are either increased (8, 50, 182, 186), decreased (96, 134, 227, 241) , or unchanged (227) in normal pregnancy. The vasoconstrictive actions of both agonists were potentiated by endothelial removal and by NOS inhibition with L-NNA (180) and L-NAME (134). NE is the endogenous neurotransmitter of the periarterial nerves in uterine arteries (179) and exhibits q-, some a2-, and P1-adrenergic activity. The vasoconstrictor effects of NE have been reported to be increased (10, 69, 149, 184) (239, 243, 244) also may be reduced during gestation, in part via an endothelial-mediated mechanism. However, these observations are also not consistent (110, 111, 160, 228) . Of these agents, the vasoconstrictor response to 5HT was not enhanced by NOS inhibitors (243). Vasoconstriction with the depolarizing agent KC1 was reported to be increased or unchanged in intact arteries or unchanged in denuded arteries by pregnancy (8, 50, 69, 186, 227, 244) . This requires more critical evaluation.
Another method used to evaluate the endotheliumdependent relaxation of uterine arteries during pregnancy is the application of NO-stimulating agents (ACh, A-23187, b ra y d k inin, etc.) to precontracted perfused uterine vascular beds ex vivo or isolated uterine arteries in vitro (75, 103, 137, 163 (Table  2 ). This vasodilatory response to ACh commenced just before midgestation and was maximal by 59 days, being lo-fold greater than nonpregnant values, and declined to 5-fold by term (term = 65 days). Bell noted that this uterine vasodilatory response was associated with the increase in plasma estradiol in pregnancy, and it also paralleled the rise in placental blood flow (17).
ACh-mediated relaxation has been reported for isolated uterine arteries in vitro, precontracted with phenylephrine (182,239), NE (152, 179), or PGF2, (110, 244) in nonpregnant and pregnant guinea pigs (16, 110, 242, 244) , rats (182), humans (178, 179), and dogs (152). However, these reports are not always in agreement, with relaxation responses being reported to be either 241) ; however, the actions of NOS inhibitors were not studied. Magness et al. (146) observed that in uterine arteries from pregnant sheep both the A-23187-induced relaxation of NE-precontracted vessels (146) and cGMP production (unpublished observations) were dependent on the production of endothelial NO.
Methodological differences rather than species differences likely account for the many inconsistencies noted above. The above studies on isolated vessels varied depending on: 1) the optimal length-tension relationship used; 2) the percent maximum contraction produced (and its stability) before relaxation with NOreleasing agents; 3) the dose and types of inhibitors used to exclude other relaxants that may be released; 4) the presence of inhibitors of nerve reuptake and release mechanisms;
and 5) the expression of data per crosssectional area or as a percent of maximum contraction. Another confounding issue in studying uterine vessels during pregnancy is that both the endothelium and VSM are morphologically altered. The VSM undergoes dramatic hypertrophy and hyperplasia (8, 36) , and the compliance and elastic modulus of the arteries are increased (88). Weiner et al. (242) sheep. This increase was specific to the uterine artery because no difference was noted in NOS activity among omental (systemic) arteries due to pregnancy status. The NOS activity was inhibited 70-80% by L-NAME. Moreover, this is the only study demonstrating that the uterine artery endothelium was the primary source of the NOS specific activity, because denuding the uterine arteries decreased NOS specific activity by as much as 77%, a decrease consistent with the fall in cGMP production observed in arteries after endothelium removal (see below). The remaining "putative NOS specific activity" in denuded vessels was near the detection limit of this assay and could not be inhibited further by L-NAME. Thus the endothelium (which accounts for ~1% of the total arterial protein content) contains virtually all of the NOS activity in the uterine vascular wall.
Endothelial production of NO can also be measured indirectly as the NO-induced increases in VSM cGMP production in arterial rings (143, 217, 247) . This technique is plausible because of the intimate proximity of the two primary cell types that comprise the vascular wall, the endothelium, and the VSM (137, 141, 143, 145, 241, 242) .
It requires inclusion of the phosphodiesterase inhibitor IBMX so that the accumulation of VSM cGMP reflects production stimulated by NO and not catabolism (143, 217, 247) . Recently Magness et al. (143) tested the hypothesis that pregnancy augments basal and ANG II-stimulated uterine artery NO production, which in turn increases VSM cGMP. Basal uterine, but not omental, systemic artery cGMP production was elevated five-to sixfold in pregnant versus nonpregnant sheep. Basal NO-mediated VSM cGMP accumulation was modulated solely by NO, since endothelium removal lowered cGMP levels 80-90% to values equivalent to the baseline arterial cGMP content. In addition, the NOS inhibitor L-NAME and the sGC inhibitor methylene blue both decreased cGMP in intact, but not denuded, uterine and omental arteries.
ANG II increased cGMP production by uterine and omental arteries from pregnant ewes. This response is controlled by NOS activity because ANG II increased cGMP only in intact and not denuded arteries. Moreover, L-NAME inhibited this ANG II-induced cGMP production, and this inhibition was reversed by L-arginine, but not D-arginine, demonstrating the stereospecificity of NOS for its endogenous substrate. The ANG II response was inhibited by methylene blue and L-NAME, whereas stimulation of VSM cGMP production with exogenous NO (i.e., SNP) was inhibited by methylene blue, but not L-NAME or endothelium removal. Therefore, ovine pregnancy is associated with increased basal and ANG II-stimulated de novo synthesis of NO production by ovine uterine artery endothelium, which in turn, activates sGC and is responsible for concomitant increases in VSM cGMP.
NOS Isoform Expression in Uterine Vasculature
The increases in uterine artery endothelium-derived NOS activity during pregnancy may be a function of increased total ecNOS, nNOS (Ca2+ sensitive, constitutive isoforms), and/or iNOS enzyme content. Magness et al. (145) addressed this issue by testing the calcium sensitivity of uterine and omental artery NOS activity and cGMP production in uterine arteries from pregnant sheep. Both uterine and omental artery NOS activity and cGMP production in Ca2+-containing media were inhibited (75~85%) by Ca2t removal plus the addition of ethylene glycol-bis( P-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), implying the presence of ecNOS and/or nNOS rather than iNOS. Weiner et al. (240) also reported that Ca2+-sensitive L-arginineto+citrulline conversion was elevated in intact uterine arteries obtained from pregnant versus nonpregnant guinea pigs. Recently, Magness and colleagues (145) reported the presence of ecNOS, but not nNOS, in uterine and systemic (omental and renal) artery endothelium as determined by immunohistochemistry and Western immunoblots. Furthermore, the expression of ecNOS protein by the uterine artery endothelium, but not VSM, was increased in pregnancy. This pregnancyrelated response thus appears not only to be cell and isoform specific, but also unique to the uterine vasculature, since the systemic artery endothelium showed only minimal or no significant changes in ecNOS with pregnancy and no expression of nNOS. There are currently no studies in the literature that evaluate the expression of the mRNAs encoding for NOS in the uterine vasculature.
The Ca2+ sensitivity of NOS activity (145, 236, 240, 247) , coupled with the lack of NOS protein expression in VSM by Western analysis (145), contrasts with a study using an in vitro bioassay (134), which suggested that there is some residual VSM NOS activity (probably iNOS) production in ephedrine-stimulated denuded uterine arteries of pregnant sheep. This study, however, did not evaluate VSM NOS activity or protein expression directly. When the endothelium was removed from uterine arteries, Magness et al. (143) observed that L-[3H] arginine-to-L-[3H] citrulline conversion and NO-mediated cGMP production were reduced to nearly nondetectable levels in the remaining VSM; neither could they be reduced further using L-NAME (143). Additional, albeit indirect, evidence is available for a lack of VSM NOS during pregnancy. With endothelium removal, the uterine and omental artery VSM cGMP production by vessels from pregnant and nonpregnant sheep (143) and the aortas from pregnant and nonpregnant rats (247) was unaltered, even in the presence of IBMX plus excess L-arginine. Therefore, these observations do not support the premise that under normal physiological conditions there is any significant NOS activity or NOS protein expression in the uterine artery VSM during pregnancy. Although the mechanism(s) controlling the specific increases in NO activity and protein expression in uterine vasculature during normal pregnancy are unclear, shear stress and flow are known to be potent stimulators of NO production (158, 168). Circulating levels of ANG II and estrogen also are elevated in pregnancy (17, 137, 138, 140, 142) and may chronically stimulate production of NO directly (143, 158, 159, 168203, 236) .
In summary, many lines of evidence suggest that a relationship exists between increases in NO production and the increase of uteroplacental blood flow during gestation; however, the final confirmation of a cause and effect relationship has yet to be directly established.
PLACENTA AND UMBILICAL CORD
In this section, we consider the evidence for NOS activity in the placenta and umbilical cord, the functional role of NO in the fetoplacental and umbilical circulations, and alterations in placental and umbilical NO during preeclampsia.
NOS in Human Placenta and Umbilical Cord
NOS was identified in villous tissue from the human term placenta by assaying conversion of radiolabeled L-arginine to L-citrulline (45, 93, 167, 172) . Enzyme activity was dependent on NADPH, tetrahydrobiopterin, and FAD as previously described for NOS. In most studies (45, 93, 172) , the NOS activity was largely dependent on calmodulin and calcium being inhibited by trifluoperizine or R-24751 and EGTA, respectively. Only a residual of activity was calcium insensitive. Placental NOS activity was unaffected by the presence or absence of magnesium ions. It was inhibited by the L-arginine analogs, L-NNA, L-NAME, and L-NMMA. By Lineweaver-Burk analysis, the K,, ranged from 2 to 15 uM and the Vmax from 5 to 50 pmol~mg-l~min-l. The V max was not affected by the route of delivery or by labor. At least two-thirds of the activity resided in the particulate fraction. Comparable enzyme characteristics were observed for placental NOS purified 3,800-fold to greater than 80% homogeneity and which was identified as the type III ecNOS by analysis of tryptic digests (79). Placental NOS activity was also detected in first trimester, late second or early third trimester, and mole villous placentas; in an enriched preparation of syncytiotrophoblast (ST) removed from the villous vascular tree; as well as in the decidual basal plate carefully dissected from the villi (41, 45, 124, 231) . Again, the NOS activity was mainly calcium sensitive.
Using monoclonal antibodies generated against ecNOS, a single -135-kDa band was identified on Western analysis in term villous placenta (29, 172; Conrad, unpublished observations was noted in the fibroblast layer of the amnion (67). In the first trimester villous placenta, NADPH-d and immunohistochemical studies identified ecNOS in the ST, but not villous cytotrophoblast (67, 156). Interestingly, both ecNOS and iNOS were detected by immunohistochemistry in trophoblast cells adjacent to dilated segments of the uteroplacental artery during early pregnancy in the guinea pig. The authors postulated that the NO contributed to the physiological dilation of these arteries in pregnancy (175).
By in situ hybridization, the mRNA for ecNOS was identified in the ST of normal term and complete mole villous placentas ( Fig. 3; Ref. 45) . Interestingly, hybridization was not apparent in the endothelium of the smaller more distal villous vessels. On Northern analysis, two mRNA transcripts of 4.1 and 5.9 kb hybridized with an ecNOS cDNA probe (79). With the use of primers to distinguish the different NOS isozymes and RNA extracted from the term placenta and positive control tissues, only the primers for ecNOS resulted in the amplification of a DNA product from the term placenta, which upon partial sequencing was identical to the human ecNOS sequence (79 (26, 33, 34, 235) . The relaxing agent generated by the umbilical vessels was identified as NO by several criteria: inhibition by methylene blue or reduced hemoglobin, a short half-life of several seconds that was decreased further by superoxide or lengthened by superoxide dismutase, generation of cGMP in the detector smooth muscle, and by chemical identification as NO or a nitroso compound.
Although the umbilical cord vessels produced NO in response to endothelium-dependent agonists, they did not relax in response to these agonists, nor did the chorionic plate vessels. Human umbilical arteries, veins, and chorionic plate vessels from term placentas preconstricted with a variety of agents failed to relax, or only minimally so, to ACh, bradykinin, histamine, ATP, ADP, substance P, and A-23187, despite having the capacity to relax in response to nitrovasodilators (90, 101, 164, 216) . In one study, indomethacin, but not L-NNA, augmented the vasoconstrictor responses of 5-HT and bradykinin in the human umbilical artery (114). In another, L-NMMA produced small contractions in chorionic plate vessels and augmented both endothelin-and 5-HT-induced contractions (74). These studies suggested a modulatory role for prostaglandins or NO on the contractions produced by 5-HT, bradykinin, and endothelin. In one study, histamine, A-23187, and L-NNA more clearly modulated the functional behavior of human umbilical arteries of earlier gestational age, suggesting developmental regulation. These results were partly explained by the observations that both basal and histamine-stimulated release of NO, as well as the sensitivity of the umbilical smooth muscle to NO decreased with gestational age (105). In contrast, Sexton et al. (216) In contrast, the endotheliumdependent agonists that typically produce vasodilation in other circulatory beds are with few exceptions (e.g., ATP) without effect in the fetoplacental circulation. The umbilical cord vessels have the capacity to produce NO in response to a variety of endothelium-dependent agonists. The potential significance of this finding is that release of NO by these conduit vessels may influence the caliber of resistance vessels downstream. On the other hand, the influence of endothelium-dependent vasodilators and inhibitors of NOS on the functional behavior of umbilical and chorionic vessels is minimal in term preparations.
Whether the impact of basal or agonist-stimulated NO on umbilical vessels is more pronounced earlier in gestation is controversial.
Preeclampsia

Few investigators
have evaluated the status of NO or NOS in placentas or umbilical cords from women with preeclampsia.
In preeclampsia, the exaggerated intervillous thrombus formation could result from reduced formation of NO by the ST leading to increased aggregation of platelets, and the reduced fetoplacental blood flow may partly arise from deficient NO production by the ST overlying the resistance vasculature in the stem villi. In contrast to expectations, however, Wang et al. (237) failed to find d ff i erences in nitrite production by villous explants from normal pregnant and preeclamptic women. Similarly, Conrad and Davis (41) observed comparable Vmax and K, values for calcium-sensitive NOS activity in villous placenta and decidual basal plate between normal pregnant and preeclamptic women. The calcium-insensitive NOS activity was 40-fold less than the calcium-sensitive activity and was also not different between normal and preeclamptic subjects. In contrast, Rutherford et al. (205) reported ' increased L-E3H]NNA binding to villous trophoblast in women with preeclampsia and/or intrauterine growth restriction.
They also observed increased NOS activity in placental homogenates of the complicated pregnancies, although differences in ecNOS mass by Western analysis were not evident. Morris et al. (167) reported a decrease in NOS activity of placental villous homogenates from pregnancies complicated by preeclampsia. By immunohistochemistry, Ghabour et al. (80) observed a redistribution of ecNOS from the basal to the apical membrane and a more diffuse rather than punctate pattern in the ST of preeclamptic compared with normal placentas. Additionally, they reported the appearance of ecNOS in the terminal villous vessels of preeclamptic placentas, which was not observed by them in normal placentas.
In the superfused umbilical artery and vein from women with preeclampsia, Pinto et al. (193) reported an 80-90% reduction in the release of NO stimulated by bradykinin compared with vessels from normal placentas (193) . The defect was not restored by larger bradykinin dosages nor by superoxide dismutase or additional L-arginine. The results suggested reduced numbers of viable endothelial cells, a specific defect in the enzymatic machinery to produce NO, and/or an abnormality of the bradykinin receptor. A recent study by Akar and colleagues (4), also using the superfusion technique, demonstrated that basal NO release was greater in the umbilical artery and vein from women with preeclampsia.
In contrast, stimulated release by histamine and bradykinin, but not by A-23187, was compromised in the umbilical artery. The responses of the umbilical vein to agonist-stimulated NO production were not different between normal and preeclamptic placentas.
They concluded that basal NO production may be increased as a compensatory measure to help offset increased fetoplacental vascular tone in preeclampsia. The expression of ecNOS by the terminal villous vessels described above and the higher concentrations of NOx in the umbilical venous blood of preeclamptic women (136) are consistent with this conclusion. A reduction in NO production by bradykinin and histamine, but not by A-23187, suggested receptor defects.
Somewhat at odds with these results are the findings of Gonzalez et al. (83) . Using the isolated perfused human cotyledon, they demonstrated that 1) L-NNA and methylene blue enhanced resting perfusion pressure of normal pregnant, but not preeclamptic preparations; 2) 5-HT produced greater increments of perfusion pressure in preeclamptic specimens; and 3) the 5-HT response was potentiated by L-NNA only in the normal pregnant cotyledons. These data suggest impairment of basal and stimulated NO activity in the fetoplacental circulation during preeclampsia (83). In contrast, sensitivity of the fetoplacental circulation to NO is most likely comparable between normal pregnancy and preeclampsia (18).
NO AND UTERINE CONTRACTILITY DURING PREGNANCY
Because the precise mechanisms for the onset of parturition remain uncertain, and preterm delivery is a major unsolved health problem, possible new mediators of uterine function are eagerly investigated.
It has been proposed that NO is an endogenous uterine relaxant that contributes to uterine quiescence during pregnancy prior to term (177, 219, 254) .
To substantiate this proposal, several criteria need to be satisfied. Can NO relax uterine myometrium?
Is NO produced in the uterus during pregnancy?
And, does uterine NO, or sensitivity to NO, decrease before the onset of parturition? Or alternatively, can NO relax myometrium independent of cGMP? In addressing these questions, attention should be paid to the state of the myometrium (nonpregnant, pregnant, or laboring) since the response to NO may vary.
Myometrial cGMP in the nonpregnant uterus has been shown to increase in vitro in response to treatment with NO donors in rats (57, 58, 120, 131, 132) , guinea pigs (22>, and humans (27). One study showed a difference between NO donors: NTG did not increase cGMP whereas SNP did (57). This difference may be accounted for by the fact that NTG requires enzymatic release of NO, whereas SNP does not. The response of myometrial cGMP to NO in the pregnant or laboring uterus has not been reported. Complete dose-response curves are also lacking. The 100 uM dose range used in all of these studies greatly exceeds the 1 uM dose range needed to relax vascular smooth muscle (121).
Myometrial relaxation in response to cGMP has been tested by using the cell-permeable nonhydrolyzable cGMP analog, 8-bromo-cGMP.
&bromo-cGMP in vitro produced relaxation of nonpregnant myometrium from rats (57, lSS>, but not human myometrium precontracted with endothelin (251). Pregnant (104, 106, 255) and labored (106, 255) rat myometrium relaxed in response to 8-bromo-cGMP, with the latter being less sensitive to the cGMP analog. The competitive cGMP antagonist (R)-p-guanosine 3',5'-cyclic monophosphorothioate reversed the relaxant effect of 8-bromoguanosine 3',5'-cyclic monophosphate on pregnant rat myometrium (104). Methacholine increased cGMP levels in nonpregnant estrogen-primed rabbit myometrium and decreased contractile force (211). However, the ex- petted correlation of cGMP level and smooth muscle relaxation as seen in vascular smooth muscle (125) was not evident in one study of nonpregnant myometrium (57), but was suggested in a less extensive study (194) . Thus there is a lack of consensus regarding the relaxant effect of cGMP on myometrium.
This may be due to species and pregnancy-induced differences. NO can relax VSM without increasing cGMP by directly opening KCa channels leading to membrane hyperpolarization (20). Consistent with this, NTG hyperpolarized the pregnant rat myometrial membrane (59); NTG relaxed nonpregnant rat myometrium without elevating cGMP levels (57); the K channel inhibitor, tetraethylammonium, but not the sGC inhibitor, methylene blue, inhibited S-nitro-L-cysteine-induced relaxation of nonpregnant monkey myometrium (123). There is evidence that KCa channels are important in human pregnancy, because myometrium contracted when these channels were blocked with iberiotoxin (9). Thus activation of sGC and/or KCa channels may mediate NO relaxation of the myometrium.
NO Donors and Myometrial Relaxation
The majority of the time, when NO donors have been applied to myometrium in vitro, reductions in contraction amplitude and/or frequency have been observed (Table 3) . Th e exceptions are as follows: 3 and 5 mM SNP did not inhibit spontaneous contractions of nonpregnant rat myometrium (57, 194) , whereas 1 uM SNP did relax nonpregnant human myometrium by 50% (251). A lo-min contractile effect of 100 uM SNP was observed in estrogen-treated nonpregnant rat myo- metrium, but only after 40 min of in vitro incubation, possibly due to stimulation of prostaglandins (73). ' Three millimolar SNP did not relax ZO-day pregnant rat myometrium in one study (194) , but 5 mM SNP did relax 18day pregnant rat myometrium in another (254). Two ml1 1 imolar NTG relaxed pregnant rat myometrial contraction induced by KC1 in one study (60), but 1 mM SNP did not in another (104). Complete dose-response curves were not reported in all studies. Some of the inconsistencies might be explained by variable inactivation of NO by oxygen (95%) routinely bubbled through organ baths (197, 204) . Non-NO effects of NO donors may also be confounding:
10 pM SNP relaxed 19-day pregnant rat myometrium only after 30 min of continuous application, and then only two of seven preparations regained contractile activity after drug washout (104). SNP is known to generate cyanide, which could inhibit myometrial contraction via the inhibition of oxidative phosphorylation (81). Gestational age differences in the myometrium studied might also account for some of the discrepant results, for example, DEA-NO was more potent at relaxing human term myometrium before the onset of labor than during labor (27). The clinically important question of the relationship between NO and relaxation of preterm human myometrium, if any, has yet to be investigated in vitro. Nevertheless, in two-thirds of the studies listed in Table 3 , NO donors did relax uterine myometrium in vitro, regardless of the species, pregnancy state, or the preconstricting agent. As early as 1882, Barnes (11) reported the use of amyl nitrite to relax the human uterus in a case of retained placenta. Many case reports of the in vivo use of NO donors as uterine relaxants have since appeared, but they lack objective measures of myometrial contractile force (7, 13, 37, 47, 56, 85, 97, 192) and placebo controls (130). Only th ree studies with small sample sizes used intrauterine pressure catheters: inhaled amyl nitrite suppressed oxytocin-induced contractions during human labor at term, but not spontaneous contractions (126). Maternal blood pressure decreased 10%. Intravenous SNAP suppressed preterm hysterotomy-induced contractions in rhesus monkeys (108), and intravenous #' NTG suppressed spontaneous term labor in sheep (98). More study is needed of the effects on maternal hemodynamics (37) and on the fetus (129) before NO donors can be embraced as uterine tocolytics for use in humans. If NO is physiologically important in maintaining uterine quiescence, one would expect it to be produced up until, but not during, parturition.
One would also expect NO to be produced by myometrial myocytes or by cells within a distance of 100 urn of myometrial myocytes to escape inactivation by hemoglobin (128).
Three different techniques have been used to provide biochemical evidence of NOS activity in the pregnant uterus (Table 4) . First, the conversion of radiolabeled L-arginine-to+citrulline has been found to occur in homogenates of pregnant rat (177) and guinea pig (238) uteri (both myometrium and decidua), as well as by pregnant human myometrium (195) . In these studies, both calcium-insensitive (iNOS type) and calciumsensitive (ecNOS and/or nNOS type) activity were observed. Rabbit (219) and human (222) decidua contained only the calcium-insensitive NOS activity, which in the rabbit was sixfold greater than in the myometrium. L-Arginine can be metabolized by enzymes other than NOS (49), and the specificity of this assay technique has not always been scrutinized.
Using a different technique, measurement of nitric oxide metabolites (NOx), 18-day gestation rat uterine explants (decidua + myometrium) demonstrated NOS activity (254, 255) , and the NOS activity in rabbit decidual homogenates was confirmed (2 19). Progesterone increased and estrogen antagonized NOx production by nonpregnant rat uterine explants (252). The uterine explant studies (254, 255) were done with and without the NOS inhibitor L-NAME, and the decreased activity at the end of pregnancy could theoretically be confounded by differences in L-arginine and L-NAME A bioassay technique has also been used to demonstrate NOS activity in the myometrium.
The substrate L-arginine was applied to longitudinal strips of myometrium from gravid rats and humans, resulting in relaxation, presumably due to NO synthesis (106, 254, 255) . Further study has suggested that the cationic charge of L-arginine, rather than release of NO from L-arginine, accounted for the relaxation (112). L-Arginine-induced relaxation of unlabored preterm and term human myometrium could not be reproduced in another study (109).
Hence, two of three techniques have provided evidence that the uterus synthesizes NO during pregnancy.
liming of Gestational
Changes in Uterine NO Production
Of the eight studies in Table 4 , which included samples from uteri in labor, five showed a decrease in NOS activity between late gestation (16-18 days in rats and 32-34 wk in humans) and spontaneous labor at term (177, 219, 220, 222, 254) . Hence there is a consensus on a decrease in uterine NOS activity at the end of pregnancy.
However, the precise timing of the decrease, when between late gestation and spontaneous labor at term, has not been completely elucidated. Only two studies measured uterine NOS activity the day before the spontaneous onset of labor (219, 220). If a decrease in uterine NO production is proposed as the cause of parturition, then more evidence is needed that substantiates a decrease in NOS activity followed within hours by the onset of parturition.
Alternatively, if decreased myometrial sensitivity to NO is involved, more evidence is needed that the decrease in sensitivity occurs at the onset of labor.
An indirect measure of uterine NOS activity and its change with advancing gestation might be provided by tissue levels of cGMP. The concentration of cGMP per milligram uterine tissue was twice as high in rat myometrium at 18 days of gestation versus nonpregnant and versus during parturition (252). In guinea pigs, uterine cGMP concentration was maximum at 0.75 gestation and was 60% less at 0.95 gestation (238) . In rabbits, myometrial cGMP was 60% less at midgestation versus nonpregnant and then was essentially zero during parturition (118). It is not known whether these differences in tissue cGMP concentrations are due only to differences in NO-stimulated synthesis or are also due to differences in cGMP catabolism. inhibited CGRP-induced relaxation, implying that CGRP stimulates nNOS, resulting in relaxation of nonpregnant rat myometrium (218). However, myometrial neurons degenerate during pregnancy (6, 249), and whether they make a significant contribution to uterine quiescence has yet to be determined.
The evidence above also suggests that the decidua may be a source of NO for myometrial quiescence. A study of 18-day gestation rat uteri showed a greater frequency of oxytocin-induced contractions in uterine rings denuded of decidua, implying the elaboration of an inhibitory factor by the decidua. In contrast, spontaneous contraction amplitude was decreased when the decidua was removed, also implying the elaboration of a excitatory factor by the decidua (223). If neuronal or decidual NO relaxed myometrium via increasing cGMP, one would expect NOS inhibitors to decrease myometrial cGMP. However, L-NAME administered intravenously to anesthetized pregnant guinea pigs did not decrease myometrial cGMP concentration per gram wet weight (238 
